Feb 23 (Reuters) - The attorney general for one of the most populous U.S. states this week urged federal drug regulators to address safety risks associated with the widely used asthma and allergy medicine Singulair, saying current warnings on the drug's packaging are insufficient, particularly for children.
Enforcement Report - Week of November 15, 2023
June 26 (Reuters) - An early magazine advertisement for Merck’s breakthrough asthma and allergy medicine, Singulair, featured a happy child, hanging upside-down from a tree. Asthmatic kids could now breathe easier, the text assured, and side effects were “usually mild” and “similar to a sugar pill.”
Health Canada Issues Recall of Pro Doc Ltée`s Montelukast chewable tablet; Out of specification
Enforcement Report - Week of May 10, 2023
Enforcement Report - Week of April 5, 2023
Health Canada Issues Recall of Impurity - Pro Doc MONTELUKAST SODIUM 5mg
Amneal Pharms LLC’s Generic Montelukast Sodium Receives Approval In US
The FDA on Wednesday said it is requiring a boxed warning and medication guide for Merck’s asthma and allergy drug Singulair (montelukast) and its generics to strengthen existing warnings about the risk of neuropsychiatric events, including suicides, linked to the drug.
The US Food and Drug Administration (FDA) on Wednesday said it is requiring a boxed warning and medication guide for Merck’s asthma and allergy drug Singulair (montelukast) and its generics to strengthen existing warnings about the risk of neuropsychiatric events, including suicides, linked to the drug.